Recent Finacing
Recent Raise
Angiochem is a clinical-stage company developing LRP-1–targeted peptide drug conjugates to cross the blood–brain barrier, advancing ANG1005 toward Phase III for leptomeningeal carcinomatosis and CNS indications.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investor
See the team members at AngioChem.
